Low PE pharma penny stock below Rs 60 jumps 14.50 per cent after reporting turnaround net profit of Rs 25 crore in FY25
The company has a market cap of over Rs 300 crore and the stock is up by 16.34 per cent from its 52-week low of Rs 49.20 per share.
On Monday, one of the Top Gainers on NSE, shares of Balaxi Pharmaceuticals Ltd, jumped 14.50 per cent to Rs 57.24 per share from its previous closing of Rs 49.99 per share. The stock’s 52-week high is Rs 151.45 per share and its 52-week low is Rs 49.20 per share. A total of 5.33 lakh shares changed hands on the NSE.
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical company that focuses on the production, stocking, selling, and supply of both branded and generic medicines. With a substantial portfolio of 610 pharmaceutical product registrations, Balaxi offers a diverse range of products, including tablets, injectables, liquids, and capsules, sourced from WHO-GMP-certified contract manufacturers located in India, China and Portugal.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
According to Quarterly Results, the net sales increased by 4 per cent to Rs 76.27 crore and net profit increased by 61 per cent to Rs 8.64 crore in Q4FY25 compared to Q3FY25. In its annual results (FY25), the net sales increased by 22 per cent to Rs 293 crore compared to FY24. The company reported a net profit of Rs 25 crore in FY25 compared to a net loss of Rs 2 crore in FY24, an increase of 1,350 per cent.
The shares of the company have a PE of 12x whereas the industry PE is 36x. As per NSE data, 66 per cent stake lies with the promoter and promoter group and the rest, about 34 per cent, is owned by public shareholders, which includes FIIs & DIIs. The company has a market cap of over Rs 300 crore and the stock is up by 16.34 per cent from its 52-week low of Rs 49.20 per share.
Disclaimer: The article is for informational purposes only and not investment advice.